Lysophosphatidic acid induces MDA-MB-231 breast cancer cells migration through activation of PI3K/PAK1/ ERK signaling

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Du, Jun ^a   Sun, Chongqi ^a   Hu, Zhenzhen ^a   Yang, Yu ^a   Zhu, Yichao ^a   Zheng, Datong ^b   Gu, Luo ^a   Lu, Xiang ^b  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; LYSOPHOSPHATIDIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; P21 ACTIVATED KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; REACTIVE OXYGEN METABOLITE; LYSOPHOSPHOLIPID; P21 ACTIVATED KINASE; PAK1 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER CELL; CELL MIGRATION; CELL MOTILITY; CELL STIMULATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; METASTASIS; SIGNAL TRANSDUCTION; BREAST TUMOR; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; DOSE RESPONSE; FEMALE; METABOLISM; TUMOR CELL LINE;

ACETYLCYSTEINE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; LYSOPHOSPHOLIPIDS; NEOPLASM METASTASIS; P21-ACTIVATED KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 78651260241     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015940     Document Type: Article

References (58)

1. Moolenaar WH (1999) Bioactive lysophospholipids and their G protein-coupled receptors. Exp Cell Res 253: 230-238.
2. Kranenburg O, Moolenaar WH (2001) Ras-MAP kinase signaling by lysophosphatidic acid and other G protein-coupled receptor agonists. Oncogene 20: 1540-1546.
3. Boucharaba A, Serre CM, Gres S, Saulnier-Blache JS, Bordet JC, et al. (2004) Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 114: 1714-1725.
4. Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clezardin P, et al. (2006) The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci U S A 103: 9643-9648.
5. Yamada T, Sato K, Komachi M, Malchinkhuu E, Tobo M, et al. (2004) Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. J Biol Chem 279: 6595-6605.
6. Panupinthu N, Lee HY, Mills GB (2010) Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression. Br J Cancer 102: 941-946.
7. Liu S, Murph M, Panupinthu N, Mills GB (2009) ATX-LPA receptor axis in inflammation and cancer. Cell Cycle 8: 3695-3701.
8. Witt AE, Hines LM, Collins NL, Hu Y, Gunawardane RN, et al. (2006) Functional proteomics approach to investigate the biological activities of cDNAs implicated in breast cancer. J Proteome Res 5: 599-610.
9. van Meeteren LA, Moolenaar WH (2007) Regulation and biological activities of the autotaxin-LPA axis. Prog Lipid Res 46: 145-160.
10. Reya T, Clevers H (2005) Wnt signalling in stem cells and cancer. Nature 434: 843-850.
11. Teuliere J, Faraldo MM, Deugnier MA, Shtutman M, Ben-Ze'ev A, et al. (2005) Targeted activation of beta-catenin signaling in basal mammary epithelial cells affects mammary development and leads to hyperplasia. Development 132: 267-277.
12. Gadalla SM, Amr S, Langenberg P, Baumgarten M, Davidson WF, et al. (2009) Breast cancer risk in elderly women with systemic autoimmune rheumatic diseases: a population-based case-control study. Br J Cancer 100: 817-821.
13. Bokoch GM (2003) Biology of the p21-activated kinases. Annu Rev Biochem 72: 743-781.
14. Dummler B, Ohshiro K, Kumar R, Field J (2009) Pak protein kinases and their role in cancer. Cancer Metastasis Rev 28: 51-63.
15. Vadlamudi RK, Kumar R (2004) p21-activated kinase 1: an emerging therapeutic target. Cancer Treat Res 119: 77-88.
16. Kumar R, Gururaj AE, Barnes CJ (2006) p21-activated kinases in cancer. Nat Rev Cancer 6: 459-471.
17. Vadlamudi RK, Adam L, Wang RA, Mandal M, Nguyen D, et al. (2000) Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. J Biol Chem 275: 36238-36244.
18. Adam L, Vadlamudi R, Mandal M, Chernoff J, Kumar R (2000) Regulation of microfilament reorganization and invasiveness of breast cancer cells by kinase dead p21-activated kinase-1. J Biol Chem 275: 12041-12050.
19. Schmitz U, Thommes K, Beier I, Vetter H (2002) Lysophosphatidic acid stimulates p21-activated kinase in vascular smooth muscle cells. Biochem Biophys Res Commun 291: 687-691.
20. Jung ID, Lee J, Lee KB, Park CG, Kim YK, et al. (2004) Activation of p21- activated kinase 1 is required for lysophosphatidic acid-induced focal adhesion kinase phosphorylation and cell motility in human melanoma A2058 cells. Eur J Biochem 271: 1557-1565.
21. Rhee S, Grinnell F (2006) P21-activated kinase 1: convergence point in PDGFand LPA-stimulated collagen matrix contraction by human fibroblasts. J Cell Biol 172: 423-432.
22. Karagiosis SA, Chrisler WB, Bollinger N, Karin NJ (2009) Lysophosphatidic acid-induced ERK activation and chemotaxis in MC3T3-E1 preosteoblasts are independent of EGF receptor transactivation. J Cell Physiol 219: 716-723.
23. Smith SD, Jaffer ZM, Chernoff J, Ridley AJ (2008) PAK1-mediated activation of ERK1/2 regulates lamellipodial dynamics. J Cell Sci 121: 3729-3736.
24. Wu WS, Tsai RK, Chang CH, Wang S, Wu JR, et al. (2006) Reactive oxygen species mediated sustained activation of protein kinase C alpha and extracellular signal-regulated kinase for migration of human hepatoma cell Hepg2. Mol Cancer Res 4: 747-758.
25. Zhang HS, Wang SQ (2006) Notoginsenoside R1 inhibits TNF-alpha-induced fibronectin production in smooth muscle cells via the ROS/ERK pathway. Free Radic Biol Med 40: 1664-1674.
26. Mehdi MZ, Azar ZM, Srivastava AK (2007) Role of receptor and nonreceptor protein tyrosine kinases in H2O2-induced PKB and ERK1/2 signaling. Cell Biochem Biophys 47: 1-10.
27. Park ER, Eblen ST, Catling AD (2007) MEK1 activation by PAK: a novel mechanism. Cell Signal 19: 1488-1496.
28. Zang M, Hayne C, Luo Z (2002) Interaction between active Pak1 and Raf-1 is necessary for phosphorylation and activation of Raf-1. J Biol Chem 277: 4395-4405.
29. Li TT, Alemayehu M, Aziziyeh AI, Pape C, Pampillo M, et al. (2009) Betaarrestin/ Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells. Mol Cancer Res 7: 1064-1077.
30. Stahle M, Veit C, Bachfischer U, Schierling K, Skripczynski B, et al. (2003) Mechanisms in LPA-induced tumor cell migration: critical role of phosphorylated ERK. J Cell Sci 116: 3835-3846.
31. Lakka SS, Jasti SL, Gondi C, Boyd D, Chandrasekar N, et al. (2002) Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro. Oncogene 21: 5601-5608.
32. Molli PR, Li DQ, Murray BW, Rayala SK, Kumar R (2009) PAK signaling in oncogenesis. Oncogene 28: 2545-2555.
33. Jiang K, Zhong B, Gilvary DL, Corliss BC, Hong-Geller E, et al. (2000) Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells. Nat Immunol 1: 419-425.
34. Kovacs EM, Ali RG, McCormack AJ, Yap AS (2002) E-cadherin homophilic ligation directly signals through Rac and phosphatidylinositol 3-kinase to regulate adhesive contacts. J Biol Chem 277: 6708-6718.
35. Hess AR, Seftor EA, Seftor RE, Hendrix MJ (2003) Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res 63: 4757-4762.
36. Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK (2008) Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 68: 1777-1785.
37. Mills GB, Moolenaar WH (2003) The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 3: 582-591.
38. Lee NY, Blobe GC (2007) The interaction of endoglin with beta-arrestin2 regulates transforming growth factor-beta-mediated ERK activation and migration in endothelial cells. J Biol Chem 282: 21507-21517.
39. Pintucci G, Moscatelli D, Saponara F, Biernacki PR, Baumann FG, et al. (2002) Lack of ERK activation and cell migration in FGF-2-deficient endothelial cells. FASEB J 16: 598-600.
40. Lee MJ, Jeon ES, Lee JS, Cho M, Suh DS, et al. (2008) Lysophosphatidic acid in malignant ascites stimulates migration of human mesenchymal stem cells. J Cell Biochem 104: 499-510.
41. Veit C, Genze F, Menke A, Hoeffert S, Gress TM, et al. (2004) Activation of phosphatidylinositol 3-kinase and extracellular signal-regulated kinase is required for glial cell line-derived neurotrophic factor-induced migration and invasion of pancreatic carcinoma cells. Cancer Res 64: 5291-5300.
42. Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, et al. (2009) Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A 106: 8368-8373.
43. Manser E, Huang HY, Loo TH, Chen XQ, Dong JM, et al. (1997) Expression of constitutively active alpha-PAK reveals effects of the kinase on actin and focal complexes. Mol Cell Biol 17: 1129-1143.
44. Slack-Davis JK, Eblen ST, Zecevic M, Boerner SA, Tarcsafalvi A, et al. (2003) PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation. J Cell Biol 162: 281-291.
45. Cheng C, Kong X, Wang H, Gan H, Hao Y, et al. (2009) Trihydrophobin 1 Interacts with PAK1 and Regulates ERK/MAPK Activation and Cell Migration. J Biol Chem 284: 8786-8796.
46. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, et al. (1998) Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem 273: 28238-28246.
47. Papakonstanti EA, Stournaras C (2002) Association of PI-3 kinase with PAK1 leads to actin phosphorylation and cytoskeletal reorganization. Mol Biol Cell 13: 2946-2962.
48. Moelling K, Schad K, Bosse M, Zimmermann S, Schweneker M (2002) Regulation of Raf-Akt Cross-talk. J Biol Chem 277: 31099-31106.
49. Wang J, Zhao Y, Kauss MA, Spindel S, Lian H (2009) Akt regulates vitamin D3- induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling. Eur J Cell Biol 88: 103-115.
50. Zugasti O, Rul W, Roux P, Peyssonnaux C, Eychene A, et al. (2001) Raf-MEKErk cascade in anoikis is controlled by Rac1 and Cdc42 via Akt. Mol Cell Biol 21: 6706-6717.
51. Cechin SR, Dunkley PR, Rodnight R (2005) Signal transduction mechanisms involved in the proliferation of C6 glioma cells induced by lysophosphatidic acid. Neurochem Res 30: 603-611.
52. Huang Q, Shen HM, Ong CN (2005) Emodin inhibits tumor cell migration through suppression of the phosphatidylinositol 3-kinase-Cdc42/Rac1 pathway. Cell Mol Life Sci 62: 1167-1175.
53. King CC, Gardiner EM, Zenke FT, Bohl BP, Newton AC, et al. (2000) p21- activated kinase (PAK1) is phosphorylated and activated by 3-phosphoinositidedependent kinase-1 (PDK1). J Biol Chem 275: 41201-41209.
54. Storz P (2005) Reactive oxygen species in tumor progression. Front Biosci 10: 1881-1896.
55. Weber DS, Taniyama Y, Rocic P, Seshiah PN, Dechert MA, et al. (2004) Phosphoinositide-dependent kinase 1 and p21-activated protein kinase mediate reactive oxygen species-dependent regulation of platelet-derived growth factorinduced smooth muscle cell migration. Circ Res 94: 1219-1226.
56. Suzukawa K, Miura K, Mitsushita J, Resau J, Hirose K, et al. (2000) Nerve growth factor-induced neuronal differentiation requires generation of Rac1- regulated reactive oxygen species. J Biol Chem 275: 13175-13178.
57. Whaley-Connell AT, Morris EM, Rehmer N, Yaghoubian JC, Wei Y, et al. (2007) Albumin activation of NAD(P)H oxidase activity is mediated via Rac1 in proximal tubule cells. Am J Nephrol 27: 15-23.
58. Turbov JM, Twaddle GM, Yang X, Liu NM, Murthy S (2002) Effects of receptor tyrosine kinase inhibitor A47 on estrogen and growth factor-dependent breast cancer cell proliferation and apoptosis in vitro. J Surg Oncol 79: 17-29.